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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER641Clinical, Molecular, and Genetic Changes in Response to an LVADJennifer L. Hall, David R. Fermin, Emma J. Birks, Paul J. R. Barton, Mark Slaughter, Peter Eckman,
Hideo A. Baba, Jeremias Wohlschlaeger, Leslie W. Miller
The use of left ventricular assist devices (LVADs) for patients with end-stage heart failure has
increased significantly in recent years, both as a bridge to transplant and as destination
therapy. This increase is driven by clinical trial results, which show that the second-generation
continuous flow devices improve survival, functional capacity, and quality of life. Hall and
colleagues review the latest clinical trials and data from the INTERMACS (Interagency
Registry for Mechanically Assisted Circulatory Support) registry on clinical outcomes. This is
supplemented with a review of the molecular, cellular, and genomic changes that underlie the
reverse remodeling of the human heart in response to an LVAD.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY653CK-MB is More Clinically Relevant for Diagnosing Post-PCI MIChris C. S. Lim, William J. van Gaal, Luca Testa, Florim Cuculi, Jayanth R. Arnold, Theodoros Karamitsos,
Jane M. Francis, Steffen E. Petersen, Janet E. Digby, Stephen Westaby, Charalambos Antoniades,
Rajesh K. Kharbanda, Louise M. Burrell, Stefan Neubauer, Adrian P. Banning
Lim and colleagues reviewed the differential implications of creatine kinase-myocardial band
(CK-MB) and troponin measurement using the universal definition of periprocedural injury
after percutaneous coronary intervention (PCI). This definition is based on elevations in
cardiac biomarker 3 times the 99th percentile of healthy subjects. A total of 32 patients
undergoing multivessel PCI were imaged with late gadolinium enhancement (LGE) cardiac
magnetic resonance (CMR) imaging. One-third of patients had an elevation in CK-MB
above the 99th percentile, but 3 times this level, and one-sixth were 3 times the 99th
percentile. Patients with CK-MB–defined myocardial infarction (MI) type 4a had evidence of
a new defect on CMR-LGE. Using cardiac troponin I, 80% of patients had a type 4a MI
but only a small minority had evidence of abnormality on CMR-LGE. These results suggest
that current troponin thresholds are over-sensitive when using the 3 times the 99th percentile
threshold.
Editorial Comment: Cindy L. Grines, Simon Dixon, p. 662(continued on page A-20)
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664egistry Shows Equivalence of Carotid Stenting
or Endarterectomy at 5 YearsPaola De Rango, Gianbattista Parlani, Fabio Verzini, Giuseppe Giordano, Giuseppe Panuccio,
Matteo Barbante, Piergiorgio Cao
De Rango and colleagues reviewed the long-term outcomes of carotid stenting (CAS)
compared with carotid endarterectomy (CEA) based on physician-guided indications. Slightly
more than 1,000 patients underwent each procedure, with selection of treatment based on
anatomy and clinical characteristics. Thirty-day stroke/death rates were similar: 2.8% in CAS
patients and 2.0% in CEA patients. Kaplan-Meier estimates of the composite of any
periprocedural stroke/death and ipsilateral stroke at 5 years after the procedure were similar.
CAS can offer efficacy and durability comparable to CEA, with benefits persisting at 5 years,
when physicians use their clinical judgment to select the appropriate technique for carotid
revascularization.ACUTE CORONARY SYNDROMES672Ticagrelor Superior to Clopidogrel in ACS Patients Who Undergo CABGClaes Held, Nils Åsenblad, Jean Pierre Bassand, Richard C. Becker, Christopher P. Cannon, Marc J. Claeys,
Robert A. Harrington, Jay Horrow, Steen Husted, Stefan K. James, Kenneth W. Mahaffey, José C. Nicolau,
Benjamin M. Scirica, Robert F. Storey, Marius Vintila, Joseph Ycas, Lars Wallentin
This post-hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial by
Held and colleagues compares the outcomes in the nearly 1,300 subjects who presented with
an acute coronary syndrome (ACS) and then underwent coronary artery bypass graft (CABG)
surgery. Subjects received either ticagrelor or clopidogrel in a double-blind, randomized
manner. The protocol recommended ticagrelor/placebo be withheld for 24 to 72 h and
clopidogrel/placebo for 5 days pre-operatively and then restarted post-operatively. For this
report, events occurring from the CABG procedure until the end of the study are reported.
The risk of the primary composite end point was significantly lower in the ticagrelor group,
and total mortality was reduced by 50%. There was no significant difference in CABG-
related major bleeding or several other bleeding-related end points to explain this difference.
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ECARDIOGENIC SHOCK
688ercutaneous Ventricular Assist Device Rapidly Restores
Hemodynamics in Severe Refractory Cardiogenic ShockBiswajit Kar, Igor D. Gregoric, Sukhdeep S. Basra, Gary M. Idelchik, Pranav Loyalka
Kar and colleagues describe their experience with a percutaneous ventricular assist device
(pVAD) in patients in severe refractory cardiogenic shock (SRCS) despite intra-aortic balloon
pump (IABP) and/or high-dose vasopressor support. The device draws blood in from the
left atrium after a transseptal puncture and returns it via the femoral artery. A total of
117 patients are included in this report, nearly one-half of whom underwent active
cardiopulmonary resuscitation immediately before or at the time of implant. Post-implant, the
cardiac index improved from a median of 0.52 to 3.0 l/(min·m2). The systolic blood pressure
nd mixed venous oxygen saturation increased from 75 to 100 mm Hg and 49 to 69,
espectively. This pVAD rapidly reversed the terminal hemodynamic compromise seen in
atients with SRCS refractory to IABP and vasopressor support.ditorial Comment: José A. Tallaj, Martı´n Cadeiras, p. 697PULMONARY EMBOLISM700Multicenter Registry Shows Low Mortality for Acute PECharles V. Pollack, Donald Schreiber, Samuel Z. Goldhaber, David Slattery, John Fanikos, Brian J. O’Neil,
James R. Thompson, Brian Hiestand, Beau A. Briese, Robert C. Pendleton, Chadwick D. Miller,
Jeffrey A. Kline
Pollack and colleagues reviewed the results from a multicenter registry designed to collect the
presenting features, testing, treatment strategies, and outcomes of patients diagnosed with an
acute pulmonary embolism (PE). Nearly 2,000 patients with confirmed acute PE were
enrolled from 22 hospitals. The race, ethnicity, and sex of the patients paralleled the overall
population. Most (79%) PE patients were employed, and two-thirds were under age 65 years.
The mortality rate directly attributed to PE was 1%, with 0.2% due to hemorrhage. These
results show that patients diagnosed with acute PE in the United States have a high
functional status and low mortality, but also suggest the need to determine the appropriate
threshold for empiric treatment when PE is suspected prior to diagnostic confirmation.(continued on page A-25)
FEBRUARY 8, 2011 (continued) A-25UPERIPHERAL ARTERIAL DISEASE707Faster Functional Decline Related to PAD in Women Than in MenMary M. McDermott, Luigi Ferrucci, Kiang Liu, Jack M. Guralnik, Lu Tian, Melina Kibbe, Yihua Liao,
Huimin Tao, Michael H. Criqui
McDermott and colleagues compared the rates of mobility loss, defined as becoming unable
to walk one-quarter mile or walk up and down 1 flight of stairs without assistance, in women
and men with lower extremity peripheral arterial disease (PAD). A total of 380 men and
women with PAD completed the 6-min walk, were assessed for mobility disability, and
underwent measures of 4-m walking velocity and computed tomography-assessed calf muscle
characteristics at baseline and annually for up to 4 years. At 4-year follow-up, women were
2.3 times more likely to become unable to walk for 6 min continuously, were 1.9 times more
likely to develop mobility disability, and had faster declines in walking velocity and the
distance achieved in the 6-min walk compared with men. These findings suggest that men
with PAD have greater lower extremity muscle reserve than women and that this may protect
them from functional decline relative to women with PAD.CONGENITAL HEART DISEASE
715se of Intravenous Gammaglobulin and Corticosteroids in the
Treatment of MAb-Mediated CardiomyopathySara M. Trucco, Edgar Jaeggi, Bettina Cuneo, Anita J. Moon-Grady, Earl Silverman, Norman Silverman,
Lisa K. Hornberger
Neonatal lupus erythematosus (NLE) results when maternal autoantibodies (MAb) pass
through the placenta. Myocardial damage is usually confined to the conduction system,
however, some can develop cardiomyopathy (CM) and endocardiofibroelastosis (EFE). Those
with diffuse MAb-CM/EFE have poor prognosis, with death or need for cardiac
transplantation in 85%. Trucco and colleagues have been empirically treating patients with
intravenous gammaglobulin (IVIG) and corticosteroid therapy for the last 12 years and herein
review their results with 20 patients. During pregnancy, maternal IVIG was given in 9 and
dexamethasone in 17. After birth, 17 infants received IVIG and/or corticosteroids. At a
median follow-up of 2.9 years, 80% of patients were alive with normal systolic ventricular
function. Treatment of MAb-CM/EFE with IVIG and corticosteroids potentially improves
the outcome of affected fetuses.(continued on page A-27)
FEBRUARY 8, 2011 (continued) A-27MCONGENITAL HEART DISEASE724Benefits of Percutaneous Pulmonary Valve Are Stable at 1 YearPhilipp Lurz, Johannes Nordmeyer, Alessandro Giardini, Sachin Khambadkone, Vivek Muthurangu,
Silvia Schievano, Jean-Benoit Thambo, Fiona Walker, Seamus Cullen, Graham Derrick, Andrew M. Taylor,
Philipp Bonhoeffer
Percutaneous pulmonary valve implantation (PPVI) acutely improves biventricular function
and exercise performance, but the long-term effects are less well-characterized. Lurz and
colleagues studied 65 subjects with magnetic resonance imaging and cardiopulmonary exercise
testing at 3 time points: pre-PPVI, within 1 month, and at 12 months post-PPVI. There was
a significant decrease in right ventricular (RV) end-diastolic volume early post-PPVI both in
patients who had pulmonary regurgitation and pulmonary stenosis. Late after intervention,
there were no further changes in RV volumes or ejection fraction. After PPVI, a prolonged
phase of maintained cardiac function is observed; however, there is no evidence for further
positive functional remodeling.OBESITY AND HEART DISEASE
732arked Weight Loss After GBS Results in
Reverse Cardiac Remodeling and Improved FunctionTheophilus Owan, Erick Avelar, Kimberly Morley, Ronny Jiji, Nathaniel Hall, Joseph Krezowski,
James Gallagher, Zachary Williams, Kevin Preece, Nancy Gundersen, Michael B. Strong, Robert C. Pendleton,
Nathan Segerson, Tom V. Cloward, James M. Walker, Robert J. Farney, Richard E. Gress, Ted D. Adams,
Steven C. Hunt, Sheldon E. Litwin
Owan and colleagues tested the hypothesis that gastric bypass surgery (GBS) for severe
obesity would favorably impact cardiac remodeling and function. Over 400 severely obese
patients undergoing GBS and a reference group of severely obese subjects that did not have
surgery had echocardiograms at baseline and again 2 years later. At 2-year follow-up, GBS
subjects had significant reductions in body mass index, waist circumference, systolic blood
pressure, heart rate, and insulin resistance. The GBS group had reductions in left ventricular
(LV) mass index and right ventricular cavity area and had increases in LV mid wall fractional
shortening. These results support the use of bariatric surgery to prevent cardiovascular
complications in severe obesity.(continued on page A-28)
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EPRE-CLINICAL RESEARCH740Load-Reducing Therapy Prevents Development of ARVC in a Mouse ModelLarissa Fabritz, Mark G. Hoogendijk, Brendon P. Scicluna, Shirley C. M. van Amersfoorth,
Lisa Fortmueller, Susanne Wolf, Sandra Laakmann, Nina Kreienkamp, Ilaria Piccini, Günter Breithardt,
Patricia Ruiz Noppinger, Henning Witt, Klaus Ebnet, Thomas Wichter Bodo Levkau, Werner W. Franke,
Sebastian Pieperhoff, Jacques M.T. de Bakker, Ruben Coronel, Paulus Kirchhof
Fabritz and colleagues used a murine model of arrhythmogenic right ventricular
cardiomyopathy (ARVC) to test whether reducing ventricular load prevents or slows
development of this cardiomoypathy. Genetically-conferred dysfunction of the mechanical
cell–cell connections, often associated with reduced expression of plakoglobin, is thought to
cause ARVC. Heterozygous plakoglobin-deficient mice (plako/) and wild-type littermates
nderwent 7 weeks of endurance training (daily swimming) and were randomized to load-
educing therapy (furosemide and nitrates) or placebo. Therapy prevented training-induced
ight ventricular enlargement in plako/ mice and reduced the frequency of ventricular
achycardias in Langendorff-perfused hearts. Load-reducing therapy may be useful for
reventing the development of ARVC in genetically susceptible subjects.ditorial Comment: Hugh Calkins, p. 751
